Phase 2 N=44 Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma
Cancer of the Gallbladder · Cancer of the Biliary Tract
Primary: Number of Participants With Objective Response — 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Phase 2 N=49 Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin
Unresectable Intrahepatic Cholangiocarcinoma
Primary: Tumor Response (Overall Response = Complete Response + Partial Response + Progressive Disease + Stable Disease) — 24; 22 participants
Phase 2 N=148 Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma · Combined Hepatocellular and Cholangiocarcinoma
Primary: Substudy 1: Objective Response Rate (ORR) — 22.3 Percentage of participants
Phase 2 N=30 Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
Resectable Cholangiocarcinoma · Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 · Stage II Intrahepatic Cholangiocarcinoma AJCC v8
Primary: Number of Participants Who Completed All Preoperative and Operative Therapy — 22 Participants
Phase 2 N=17 CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
Adult Primary Cholangiocellular Carcinoma · Advanced Adult Primary Liver Cancer · Cholangiocarcinoma of the Extrahepatic Bile Duct
Primary: Overall Survival — 4.7; 1.6; 3.94 months
Phase 2 N=105 S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Stratum-specific (R0 and R1) 2-year Overall Survival — 67; 60 percentage of participants
Phase 2 N=57 S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Response — 7; 6; 12; 15 participants
Phase 2 N=43 A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Metastatic Biliary Tract Carcinoma
Primary: Progression-free Survival (PFS) — 3.58 months
Phase 2 N=74 Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
Cholangiocarcinoma
Primary: Progression-Free Survival (PFS) Rate at 6 Months (Proportion of Participants Alive and Progression-Free at 6 Months) — 0.605 proportion of participants
Phase 2 N=58 Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study
Colorectal Cancer With Non Resectable Hepatic Metastasis
Primary: Progression-free Survival Rate at 9 Months — 30; 26 Participants
Phase 2 N=19 Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma
Bile Duct Cancer · Intrahepatic Cholangiocarcinoma · Cholangiocarcinoma of the Extrahepatic Bile Duct
Primary: Median Progression Free Survival (PFS) — 1.8 months
Phase 2 N=8 MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
Advanced Adult Hepatocellular Carcinoma · Localized Non-Resectable Adult Liver Carcinoma · Recurrent Adult Liver Carcinoma
Primary: Overall Response Rate (Complete and Partial Response) as Defined by RECIST 1.1 — 0 patients
Phase 2 N=40 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
Extrahepatic Bile Duct Adenocarcinoma · Gallbladder Adenocarcinoma · Gallbladder Adenocarcinoma With Squamous Metaplasia
Primary: Progression-free Survival — 2 months
Phase 2 N=8 Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma
Cholangiocarcinoma
Primary: Objective Response Rate (ORR) — 0; 0 Participants
Phase 2 N=38 Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease
Metastatic Breast Cancer · Liver Metastases
Primary: Response Rate — 2; 13; 21; 1 Participants
Phase 2 N=34 A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy
Hepatic Cancer
Primary: Treatment Response — 16; 14; 4 Participants
Phase 2 N=5 Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Unresectable Intrahepatic Cholangiocarcinoma
Primary: Objective Response Rate (ORR) Per mRECIST (Modified RECIST) — 1 Participants
Phase 2 N=28 Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
Advanced Bile Duct Carcinoma · Advanced Gallbladder Carcinoma · Refractory Bile Duct Carcinoma
Primary: Progression-free Survival (PFS) — 37.0 percentage of participants
Phase 2 N=39 Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Progression-Free Survival — 51 percentage of participants
Phase 2 N=8 Trial of IRE in Cholangiocarcinoma
Cholangiocarcinoma
Primary: Number of Patients Experiencing a Clinically Relevant Complications — 1; 7 Participants
Phase 2 N=97 Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO)
Adenocarcinoma
Primary: Progression-free Survival (PFS) — 91; 148 days
Phase 2 N=39 Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Cancer of the Bile Duct
Primary: Overall Survival (OS) at 6 Months — 7.9 months
Phase 2 N=26 Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: Proportion of Patients Demonstrating Objective Response (PR+CR) as Defined by RECIST — 0 patients
Phase 2 N=43 A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
Metastatic Cholangiocarcinoma · Cholangiocarcinoma · Pancreatic Cancer
Primary: Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1) — 0; 3 Participants
Phase 2 N=75 Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
Biliary Tract Neoplasms
Primary: The Percentage of Patients Alive and Without Progression at 6 Months Following the Initiation of Treatment — 59.4; 21.2 percentage of participants
Phase 2 N=70 Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab
Colon Cancer With Metastases to the Liver
Primary: Tumor Response — 31; 16 participants
Phase 2 N=46 Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
Adult Primary Hepatocellular Carcinoma · Localized Unresectable Adult Primary Liver Cancer · Recurrent Adult Primary Liver Cancer
Primary: Progression-free Survival — 65 percentage of participants
Phase 2 N=50 A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers
Cholangiocarcinoma Cancer · Gallbladder Cancer · Pancreatic Cancer
Primary: Incidence of Severe Toxicities — 20 percentage of participants
Phase 2 N=42 First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma
Advanced Biliary Tract Carcinoma
Primary: MTD of MEK162 - Phase I — 45 mg